Chemotherapy in recurrent heat and neck cancer.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001761:Bleomycin / Q000009:adverse effects / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005472:Fluorouracil / Q000627:therapeutic use; D006257:Head; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects / Q000627:therapeutic use; D007269:Injections, Intra-Arterial; D007273:Injections, Intramuscular; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009369:Neoplasms / Q000188:drug therapy*; D014747:Vinblastine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D003561:Cytarabine; D001761:Bleomycin; D014750:Vincristine; D014747:Vinblastine; D003520:Cyclophosphamide; D005472:Fluorouracil; D006918:Hydroxyurea; D008727:Methotrexate